These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 18221052)

  • 1. Inhibitors of steroidal cytochrome p450 enzymes as targets for drug development.
    Baston E; Leroux FR
    Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):31-58. PubMed ID: 18221052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P450-dependent enzymes as targets for prostate cancer therapy.
    De Coster R; Wouters W; Bruynseels J
    J Steroid Biochem Mol Biol; 1996 Jan; 56(1-6 Spec No):133-43. PubMed ID: 8603034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 17alpha-hydroxylase/17,20-lyase (p450(17alpha)) inhibitors in the treatment of prostate cancer: a review.
    Owen CP
    Anticancer Agents Med Chem; 2009 Jul; 9(6):613-26. PubMed ID: 19601745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of CYP 17, a new strategy for the treatment of prostate cancer.
    Hartmann RW; Ehmer PB; Haidar S; Hector M; Jose J; Klein CD; Seidel SB; Sergejew TF; Wachall BG; Wächter GA; Zhuang Y
    Arch Pharm (Weinheim); 2002 Apr; 335(4):119-28. PubMed ID: 12112031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel functionalized 5-(phenoxymethyl)-1,3-dioxane analogs exhibiting cytochrome P450 inhibition: a patent evaluation WO2015048311 (A1).
    Schroeder RL; Tram P; Liu J; Foroozesh M; Sridhar J
    Expert Opin Ther Pat; 2016; 26(1):139-47. PubMed ID: 26514241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Advances in the study of steroidal inhibitors of cytochrome P45017alpha].
    Du JJ; Chen HL; Li YC
    Yao Xue Xue Bao; 2013 Jan; 48(1):25-31. PubMed ID: 23600137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective dual inhibitors of CYP19 and CYP11B2: targeting cardiovascular diseases hiding in the shadow of breast cancer.
    Hu Q; Yin L; Hartmann RW
    J Med Chem; 2012 Aug; 55(16):7080-9. PubMed ID: 22861193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The adrenocortical tumor cell line NCI-H295R as an in vitro screening system for the evaluation of CYP11B2 (aldosterone synthase) and CYP11B1 (steroid-11beta-hydroxylase) inhibitors.
    Müller-Vieira U; Angotti M; Hartmann RW
    J Steroid Biochem Mol Biol; 2005 Aug; 96(3-4):259-70. PubMed ID: 15985365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of 17alpha-hydroxylase/17,20-lyase (CYP17): potential agents for the treatment of prostate cancer.
    Njar VC; Brodie AM
    Curr Pharm Des; 1999 Mar; 5(3):163-80. PubMed ID: 10066888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2).
    Zimmer C; Hafner M; Zender M; Ammann D; Hartmann RW; Vock CA
    Bioorg Med Chem Lett; 2011 Jan; 21(1):186-90. PubMed ID: 21129965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of novel 17alpha-hydroxylase/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo.
    Haidar S; Ehmer PB; Barassin S; Batzl-Hartmann C; Hartmann RW
    J Steroid Biochem Mol Biol; 2003 Apr; 84(5):555-62. PubMed ID: 12767280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzyme-activated inhibitors of steroidal hydroxylases.
    Johnston JO; Wright CL; Holbert GW
    J Steroid Biochem Mol Biol; 1995 Jan; 52(1):17-34. PubMed ID: 7857870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stepwise binding of inhibitors to human cytochrome P450 17A1 and rapid kinetics of inhibition of androgen biosynthesis.
    Guengerich FP; McCarty KD; Chapman JG; Tateishi Y
    J Biol Chem; 2021 Aug; 297(2):100969. PubMed ID: 34273352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Environmental inhibitors of the expression of cytochrome P450 17A1 in mammals.
    Peng Z; Xueb G; Chen W; Xia S
    Environ Toxicol Pharmacol; 2019 Jul; 69():16-25. PubMed ID: 30921671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of p450 17 as a new strategy for the treatment of prostate cancer.
    Leroux F
    Curr Med Chem; 2005; 12(14):1623-9. PubMed ID: 16022662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls.
    Hille UE; Hu Q; Vock C; Negri M; Bartels M; Müller-Vieira U; Lauterbach T; Hartmann RW
    Eur J Med Chem; 2009 Jul; 44(7):2765-75. PubMed ID: 19211174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP17- and CYP11B-dependent steroid hydroxylases as drug development targets.
    Hakki T; Bernhardt R
    Pharmacol Ther; 2006 Jul; 111(1):27-52. PubMed ID: 16426683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of cytochromes P450 with xanthone-based molecules: from aromatase to aldosterone synthase and steroid 11β-hydroxylase inhibition.
    Gobbi S; Hu Q; Negri M; Zimmer C; Belluti F; Rampa A; Hartmann RW; Bisi A
    J Med Chem; 2013 Feb; 56(4):1723-9. PubMed ID: 23363058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and evaluation of novel steroidal oxime inhibitors of P450 17 (17 alpha-hydroxylase/C17-20-lyase) and 5 alpha-reductase types 1 and 2.
    Hartmann RW; Hector M; Haidar S; Ehmer PB; Reichert W; Jose J
    J Med Chem; 2000 Nov; 43(22):4266-77. PubMed ID: 11063622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the potential of polyphenols as a CYP17 inhibitor free of adverse corticosteroid elevation.
    Lin CJ; Cheng LC; Lin TC; Wang CJ; Li LA
    Biochem Pharmacol; 2014 Aug; 90(3):288-96. PubMed ID: 24875446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.